COVID-19, Coronavirus disease COVID-19, coronavirus disease, SARS-CoV-2, 2019-nCoV
Conditions
Interventions
Administration of COVID-19 convalescent plasma 200 mL collected from patients recovered from COVID-19
COVID-19 convalescent plasma therapy, Immunoglobulin therapy
Sponsors
Saito Sho
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Written consent obtained from the patient or his/her legal representative. 2) COVID-19 diagnosed by PCR, LAMP, etc. and was admitted. 3) Patients who satisfy the following at admission: A) SpO2 <= 94% or B) require supplimental oxygen. 4) 20 years or older at enrollment
Exclusion criteria
Exclusion criteria: 1) Pregnant or breastfeeding at enrollment 2) Unable to conduct blood transfusion due to religious reasons 3) Enrolled in other COVID-19 intervension study 4) Previously administered with COVID-19 convalescent plasma 5) Known allergy to blood products 6) Deficiency of plasma protein, such as IgA 7) Not appropriate to enroll determined by the PI for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Use of ventilator or death at 14 days post-administration | — |
Secondary
| Measure | Time frame |
|---|---|
| SARS-CoV-2 virus copy tested in nasopharynx swab at 14 days post administration, clinical recovery at 14 days post administration, chronological change in blood test results, adverse reaction occurence after administration | — |
Contacts
Public ContactSho Saito
National Center for Global Health and Medicine, Disease control and prevention center
Outcome results
None listed